Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 18/20 | 0.74 |
| ▸ | MMP13 | P45452 | 5/20 | 0.74 |
| ▸ | MMP9 | P14780 | 3/20 | 0.74 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6658737 | 0.90 | ADAM17 (0.78) | ADAM17MMP13MMP9MMP2MMP1 | |
| SCHEMBL3937230 | 0.85 | ADAM17 (1.00) | ADAM17MMP13MMP9MMP1 | |
| SCHEMBL6655813 | 0.79 | ADAM17 (0.59) | ADAM17MMP13MMP9MMP1 | |
| SCHEMBL7324015 | 0.77 | ADAM17 (0.70) | ADAM17MMP13MMP9MMP1 | |
| SCHEMBL7324053 | 0.74 | ADAM17 (0.72) | ADAM17MMP13MMP9MMP1 | |
| SCHEMBL7326202 | 0.72 | ADAM17 (0.59) | ADAM17MMP13MMP9MMP1 | |
| SCHEMBL6657452 | 0.72 | ADAM17 (0.75) | ADAM17MMP13MMP9MMP1 | |
| SCHEMBL6787647 | 0.72 | ADAM17 (0.51) | ADAM17MMP13MMP9MMP2MMP1 | |
| SCHEMBL6267555 | 0.70 | ADAM17 (0.48) | ADAM17MMP13MMP9MMP2TSHR | |
| SCHEMBL9789830 | 0.70 | ADAM17 (0.51) | ADAM17MMP13MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-10-10 | — | — | US | disclosed |
| US-6340691-B1 | TREATMENT OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN CYANAMID COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1147080-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044713-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | MMP12, MMP17, MMP14 | ADAM17 7/4885MMP13 12/4885MMP9 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.